Anika Therapeutics, Inc. - 8-K Filing

Anika Therapeutics reports Q2 revenue of $32.6M with record Commercial Channel sales and raises full-year guidance (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ANIK

Read the full article at SEC EDGAR

More Regulatory news